Tenaya Therapeutics Inc

Tenaya Therapeutics reports Q1 2026 results: $81 M cash reserve, Alnylam partnership, and progress on gene therapies for heart disease.

Tenaya Therapeutics’ 2025 annual report reveals shareholder votes on directors, auditor, and equity plan amid heart‑disease biotech volatility.

Tenaya Therapeutics reports 2025 Q4 results, fast‑track gene‑therapy data, $55M raise, and plans to advance heart‑disease cures and muscular‑disease drugs.

Tenaya Therapeutics is a biotech firm focused on curative therapies for heart disease, offering investors insight into its 2026 goals, market performance, and future potential.

Tenaya Therapeutics (TENA) seeks to cure heart disease with innovative biopharma. Explore its 2026 roadmap, market outlook, and investor insights.

Tenaya Therapeutics raises $60 million after lifting its MyPEAK‑1 hold, giving new capital to fast‑track TN‑201 gene therapy for heart disease.

Tenaya Therapeutics is pioneering heart‑disease cures, targeting root causes to transform cardiovascular care despite current financial volatility.

Tenaya Therapeutics is pioneering curative heart‑disease therapies in San Francisco, aiming to tackle root causes with R&D‑driven innovation—explore the future of cardiovascular cures.

Tenaya Therapeutics, a biotechnology company based in San Francisco, is working to revolutionize patient outcomes and combat heart disease through the development of curative therapies that target the underlying causes of the condition.

Tenaya Therapeutics, a biotech company aiming to revolutionize heart disease treatment, faces financial uncertainty and volatility, leaving investors to question whether its mission is a beacon of hope or a market mirage.